A Study to Test How Safe, Effective and How Body’s Responds to the Combination of Mosunetuzumab and Pirtobrutinib Together to Treat Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia

Status

Recruiting

Phases

Phase 1

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2024-514152-32-00

Acronym

BO45287

Enrollment

Registered

2025-09-25

Start date

2025-10-06

Completion date

Unknown

Last updated

2026-01-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Relapsed or Refractory Chronic Lymphocytic Leukemia (R/R CLL)

None listed

Sex/Gender

All

Age

18 Years to No maximum

France, Poland, Spain

None listed

Source: EU CTIS · Data processed: Feb 4, 2026